Skip to main content

Table 4 Analysis of cost effectiveness

From: Pharmacoeconomic effect of compliance with pharmacist’s intervention based on cancer chemotherapy regimens: a cohort study

 

Total n = 96

Complying group n = 58

Non-complying group n = 38

P value

Number using G-CSF

56 (58.3%)

33 (56.9%)

23 (60.5%)

0.8572)

Duration of G-CSF (days)

14.8 ± 10.8

10.7 ± 14.8

20.7 ± 22.3

0.0491)

Total cost G-CSF (days)

279,731

112,763

166,968

 

 Cost of outpatient visit (dollar)

26,131

9,306

16,825

 

 Cost of hospitalization (dollar)

253,600

103,457

150,143

 

NRC (dollar/patient)

2,914 ± 594

1,944 ± 412

4,394 ± 837

0.0441)

RDI (%)

82.9 ± 13.5

85.2 ± 10

79.3 ± 15

0.0211)

  1. Data are expressed as the mean (SD) or number (%).1)unpaired t-test, 2)Fisher’s exact test. ECOG PS, Eastern Cooperative Oncology Group performance status. NRC, neutropenia-related costs. RDI, relative dose intensity.